Charles Schwab Investment Management Inc. Buys 20,346 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Charles Schwab Investment Management Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 387,187 shares of the company's stock after buying an additional 20,346 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.60% of Kymera Therapeutics worth $15,577,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after acquiring an additional 270 shares during the last quarter. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Quarry LP bought a new position in shares of Kymera Therapeutics during the third quarter worth $95,000. Thrivent Financial for Lutherans acquired a new position in shares of Kymera Therapeutics in the 3rd quarter valued at $313,000. Finally, Walleye Capital LLC bought a new stake in shares of Kymera Therapeutics in the 3rd quarter valued at $472,000.

Insider Activity

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock valued at $455,202 in the last quarter. Company insiders own 15.82% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms have issued reports on KYMR. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a "market perform" rating and a $55.00 target price for the company. Wells Fargo & Company upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. HC Wainwright raised their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target for the company. Finally, BTIG Research started coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a "buy" rating and a $60.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Kymera Therapeutics Stock Performance

KYMR traded up $1.16 on Monday, hitting $33.70. 416,570 shares of the company were exchanged, compared to its average volume of 513,369. The stock's fifty day moving average is $36.79 and its 200-day moving average is $42.27. Kymera Therapeutics, Inc. has a 12 month low of $29.07 and a 12 month high of $53.27. The company has a market cap of $2.19 billion, a PE ratio of -14.40 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.